Safety evaluation of desloratadine in allergic rhinitis

  title={Safety evaluation of desloratadine in allergic rhinitis},
  author={Vanesa Gonz{\'a}lez-N{\'u}{\~n}ez and Antonio Lu{\'i}s Valero and Joaquim Mullol},
  journal={Expert Opinion on Drug Safety},
  pages={445 - 453}
Introduction: Desloratadine is a biologically active metabolite of second-generation antihistamine loratadine. It is also indicated for the treatment of allergic diseases, including allergic rhinitis. Areas covered: A Medline search was conducted to identify preclinical and clinical studies of desloratadine. This was supplemented with additional articles obtained from online sources. The focus of this review is on the safety profile of desloratadine. Expert opinion: The review of these data… 

Rupatadine: global safety evaluation in allergic rhinitis and urticaria

The review of data indicates that rupatadine is highly selective for histamine H1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines.

Desloratadine: a guide to its use in allergic disorders

Oral desloratadine, an effective and well-tolerated second-generation antihistamine, is indicated for the once-daily treatment of the symptoms of allergic rhinitis and urticaria in paediatric and

The role of desloratadine in the treatment of allergic rhinitis and urticaria

Desloratadine is one of the better-known and tested second-generation antihistamines and is effective in relieving nasal symptoms (sneezing, congestion, blockage) and skin problems (redness, swelling, pruritus).

Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects

It is hypothesize that desloratadine may enter the CNS and that it hence in rare cases may cause a clinically relevant state of depression, a relation that patients and their treating physicians should be made aware of.

Statistical study on the incidence of allergic diseases treated with desloratadine and levocetirizine at "Atopia" Allergology Medical Center, Iaşi, Romania.

The most common allergic diseases treated with desloratadine or levocetirizine, second-generation antihistamines were urticaria, allergic rhinoconjunctivitis, allergic bronchitis, and allergic asthma.

The role of endothelin-1 and endothelin receptor antagonists in allergic rhinitis inflammation: ovalbumin-induced rat model.

ET-1 is one of the mediators that impact AR development and ET-1 antagonists can be useful for symptom control and for decreasing allergic inflammation in AR patients.

Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine

At therapeutic doses, desloratadine did not bind significantly to brain H1Rs and did not induce any significant sedation, and subjective sleepiness did not significantly differ among subjects receiving the two antihistamines and placebo.

Characterization of the chloroquine‐induced mouse model of pruritus using an automated behavioural system

The use of an automated integrated behavioural assessment in CQ‐induced pruritus makes the assay suitable for screening purposes and allows for a correct interpretation of the antipruritic effect of the compounds evaluated.

Desloratadine Exposure and Incidence of Seizure: A Nordic Post-authorization Safety Study Using a New-User Cohort Study Design, 2001–2015

This study found an increased incidence rate of seizure during DL exposed periods as compared to unexposed periods among individuals younger than 20 years, and no difference in incidence Rate of seizure was observed in adults between DL exposed and unexposed.

Pharmacokinetics and Tissue Distribution of Loratadine, Desloratadine and Their Active Metabolites in Rat based on a Newly Developed LC-MS/MS Analytical Method.

The tissue distribution study shows that LOR, DL and their active metabolites were widely distributed in the liver, spleen, thymus, heart, adrenal glands and pituitary gland, suggesting that Loratadine may have a greater tendency to distribute in the heart than its metabolites.



Desloratadine: an update of its efficacy in the management of allergic disorders.

Although comparative studies with second-generation and other recently developed H(1)-antihistamines are needed to define the drug's clinical profile more clearly, desloratadine can be expected to claim a prominent place in the management of allergic disorders in general, and in the amelioration of specific symptoms of allergy in patients with such disorders.

Review of Desloratadine Data Using the ARIA Guidelines

Desloratadine is a powerful and selective H1 receptor blocker, without clinically relevant pharmacokinetic interference by foods, medications, or intestinal transport proteins, nor interference with cytochrome P 450 3A (CYP3A), and presenting additive antiallergic activities.

Desloratadine: a nonsedating antihistamine.

Data suggest that desloratadine has antiinflammatory and decongestant activity, and appears to be a "me-too" agent, with no major differences compared with other second-generation antihistamines.

The pharmacologic profile of desloratadine: a review

  • B. Henz
  • Medicine, Biology
  • 2001
Desloratadine had no effects on the corrected QT interval (QTc) when administered alone, at high dose, or in combination with ketoconazole or erythromycin, and preclinical studies show that deslor atadine does not interfere with HERG channels or cardiac conduction parameters even at high doses.

The Safety and Efficacy of Desloratadine for the Management of Allergic Disease

Overall, current data indicate that desloratadine is a safe and effective treatment for allergic diseases, and it has been shown to improve patients’ quality of life.

Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug

  • D. Agrawal
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2001
Clinically, desloratadine effectively controls both nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR), including nasal congestion and is effective in the treatment of chronic idiopathic urticaria and improves quality of life and is well-tolerated.

Safety of desloratadine syrup in children

Two double-blind, placebo-controlled, parallel-group, single-center studies demonstrate the safety and tolerability of desloratadine syrup in children aged 2 years–11  years with AR or CIU.

Antihistamines in late-phase clinical development for allergic disease

  • L. Salmun
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 2002
The broad anti-inflammatory properties of desloratadine and mizolastine, which distinguish these agents from other H1 antagonists in clinical development, suggest they may have a more profound impact on the underlying disease in patients suffering from different forms of allergy.

Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis.

Desloratadine rapidly and safely reduced the symptoms of perennial allergic rhinitis, and its efficacy did not diminish during 4 weeks of treatment.

Therapeutic points of intervention and clinical implications: role of desloratadine

Allergic rhinitis, a major chronic airway disease that is a risk factor for asthma, warrants extended diagnostic procedures and well‐tolerated therapy that encompasses the entire airway, addresses multiple steps in the allergic inflammatory cascade, and is effective on nasal, ocular, dermal, asthma, and total symptoms.